A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma

Trial Profile

A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Glycopyrrolate (Primary) ; Olodaterol/tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Pearl Therapeutics
  • Most Recent Events

    • 22 Mar 2018 Status changed from active, no longer recruiting to recruiting.
    • 19 Mar 2018 Planned End Date changed from 15 Feb 2019 to 24 May 2019.
    • 19 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top